Collectively, these findings suggest that IGFBP2 is downregulated in AEC2 cells and its targeted expression may regulate SARS-CoV-2-induced inflammation, and therefore yield therapeutic options for patients with COVID-19. Here, IGFBP2 is linked to COVID-19.